Published March 2026

The FDA Knew About Suboxone Dental Risks Since 2022 — Why Didn't They Act Sooner?

The FDA issued its Drug Safety Communication about Suboxone and dental damage in June 2022. But the adverse event reports had been piling up for years before that. The warning was overdue — and the delay had real consequences for millions of patients.

How the FDA's Safety System Is Supposed to Work

The FDA maintains a system called FAERS — the FDA Adverse Event Reporting System. When a patient, doctor, or pharmacist reports a side effect from a medication, that report goes into the FAERS database. The FDA monitors these reports to identify safety signals: patterns that suggest a drug may be causing harm that wasn't captured in clinical trials.

This system is reactive rather than proactive. It depends on reports being filed, patterns being detected, and agency staff having bandwidth to investigate. It's imperfect. But it's the primary mechanism by which post-market drug safety issues are identified and addressed.

For Suboxone dental damage, reports in FAERS began appearing years before the 2022 warning. The acidic pH of the film — measurable in a basic laboratory setting — was not a secret. The mechanism by which acid dissolves tooth enamel is not cutting-edge science. So the question of why it took until 2022 for the FDA to require a warning is a reasonable one to ask.

What the FAERS Data Shows

A review of FAERS reports for buprenorphine sublingual products shows dental adverse events reported over a period of years. The reports included serious outcomes: multiple tooth extractions, complete tooth loss, need for implants and full-mouth reconstruction. These weren't minor inconveniences. They were life-altering injuries being documented in the federal adverse event system while millions of patients continued to use the product without any warning.

The FDA's 2022 warning stated that as of November 2021, the agency had identified 305 cases of dental adverse events associated with buprenorphine sublingual products, including 26 cases of complete tooth loss. The agency acknowledged that this was almost certainly an undercount — adverse event reporting is voluntary and estimated to capture only a fraction of actual occurrences.

Three hundred and five documented dental adverse events. Twenty-six complete tooth loss cases. And no warning label for years after these reports accumulated.

The Manufacturer's Role

The FDA doesn't operate in isolation. Drug manufacturers are legally required to report safety information to the FDA, monitor their products for adverse events, and update labeling when new safety information becomes available. They're not passive spectators waiting for the FDA to tell them their product is dangerous.

Indivior PLC — the primary manufacturer of Suboxone film — had access to the same FAERS data the FDA did. They had research and development teams familiar with the acidic pH of their product. They had a pharmacovigilance operation designed to monitor safety signals. The question of what they knew and when they knew it is central to the litigation now being pursued by thousands of claimants.

The FDA's 2022 warning also revealed that the agency had reached out to the manufacturers and requested labeling changes — a process that itself takes time and involves negotiation. The manufacturers could have updated their labels voluntarily before the FDA required it. They didn't.

The Discovery Rule and Why the Timeline Matters

For patients filing claims, the 2022 FDA warning is legally significant for another reason: it's often the clearest marker of when the connection between Suboxone film and dental damage became publicly known. In states that apply the discovery rule to pharmaceutical injury claims, the statute of limitations may start from when you knew or reasonably should have known about the causal connection — not from when the damage first appeared.

For many patients, June 2022 — or whenever they personally learned about the warning — is a reasonable starting point for that analysis. If you were diagnosed with dental damage before 2022 but attributed it to something else, the discovery rule may protect your ability to file.

This is why the FDA warning, and the timeline around it, matters so much legally. It's not just regulatory history. It's potentially the starting gun for your filing window.

The Broader Pattern

The Suboxone dental warning story isn't unique. It fits a pattern seen in pharmaceutical regulation repeatedly: a product is approved based on clinical trial data that doesn't capture long-term or population-wide harms, adverse events accumulate in post-market reporting, and a warning eventually follows — sometimes decades later.

Depo-Provera and meningioma. Transvaginal mesh and pelvic floor damage. Talc-based products and ovarian cancer. In each case, the signal existed in the data long before regulators acted. In each case, patients bore the harm while regulatory processes moved at bureaucratic speed.

The lawsuits that follow these patterns aren't just about individual compensation. They're about creating accountability in the system — consequences that might make the next manufacturer think twice before sitting on safety data and hoping no one notices.